www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024

« Back

Annual general meeting of ALK-Abelló A/S held on 12 March 2014

March 12, 2014

PDF Version

Supporting Materials:
FM_11_14UK_12032014.pdf

 

Copenhagen, 2014-03-12 18:06 CET (GLOBE NEWSWIRE) --  

At ALK's (ALKB:DC / OMX: ALK B / AKABY / AKBLF) annual general meeting held on 12 March 2014, Steen Riisgaard was re-elected Chairman and Christian Dyvig was re-elected Vice Chairman of the Board of Directors. Lene Skole, executive vice president of Coloplast, was elected as a new member of the Board of Directors. 

Furthermore the annual general meeting transacted the following business: 

  • Adoption of the proposal that future annual reports will be prepared and produced in English only. The resolution will be incorporated in the Articles of Association.
     
  • Adoption of the annual report 2013 and discharge of the Board of Directors and Board of Management.
     
  • Declaration of an ordinary dividend of DKK 5.00 per A/B share of DKK 10.
     
  • Approval of the remuneration to the Board of Directors for the present year. The remuneration remains unchanged compared with 2013.
     
  • Adoption of the proposal that in future the Chairman and the Vice Chairman of the Board of Directors shall be elected by the general meeting. The adoption of the resolution results in amendments to the Articles of Association.
     
  • Thorleif Krarup, Anders Gersel Pedersen and Jakob Riis were re-elected to the Board of Directors. Jes Østergaard did not seek re-election.
     
  • DELOITTE Statsautoriseret Revisionspartnerselskab was re-appointed as the company's auditor.
     
  • For the period until 11 March 2019, the Board of Directors was authorised to let the company acquire own B shares with a nominal value of up to 10% of the share capital at the market price for B shares on the date of acquisition, subject to a deviation of up to 10%.
     
  • Minor adjustments of the general guidelines for incentive payments to the Board of Management were approved.
     
  • For the period up to and including the day of the annual general meeting to be held in 2019, the Board of Directors was authorised to increase the company's share capital by issue of new shares with a nominal value of up to DKK 10,128,360, equivalent to A shares with a nominal value of up to DKK 920,760 and B shares with a nominal value of up to DKK 9,207,600. The adoption of the resolution results in amendments to the Articles of Association. 

ALK-Abelló A/S 

For further information please contact: Jens Bager, President and CEO, tel. +45 4574 7576

 

  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved